Skip to content

Advertisement

  • Meeting abstract
  • Open Access

Cloned HTLV-1+CD4+, but not CD8+, T-cells display an oncogenic miRNome

  • 1,
  • 2,
  • 3,
  • 1,
  • 3 and
  • 1Email author
Retrovirology20118 (Suppl 1) :A169

https://doi.org/10.1186/1742-4690-8-S1-A169

  • Published:

Keywords

  • Transcriptome Data
  • Clonal Expansion
  • Cell Cycling
  • Prominent Effect
  • Untransformed Cell

HTLV-1 persistence in vivo relies on the persistent clonal expansion of its host cells. These are CD4+ and CD8+ T cells, yet ATL is regularly CD4+. Accordingly, untransformed HTLV-1+CD4+ but not CD8+ T cells cloned from carriers cumulate the features of preleukemic cells, including multinuclearity, chromatin bridges, increased cell cycling and inappropriate telomerase activity. MicroRNAs (miR) modify the maturation of a plethora of T-cells RNA and their deregulation would therefore constitute an appropriate explanation for the Tax-dependent or -independent pleiotropic changes in the phenotype of HTLV-1+CD4+ T cells. As the miRNome of naturally infected untransformed cells has not been investigated to date, we assessed the miR expression profiling of T cells cloned from carriers. Microarray results, confirmed by quantitative RTPCR, showed that, upon infection, CD4+ and CD8+ clones yielded aberrant expression of 15 distinct miRs including miR-34b and miR-494 that were respectively over- and underexpressed in both compartments. The more prominent effect of the infection consisted in the CD4+-restricted overexpression of the cancer-related miRs miR-21, -27b and -23b associated with the CD4+-restricted downregulation of the proapoptotic miR-15 and -16. Data were extended by the analysis of 40 additional CD4+ clones (20 infected). Crossing the miRNome against the whole transcriptome data identified putative miR-targeted genes. In silico, those targeted by miR-23b and -27b defined 2 hitherto unknown pathways involving the cell cycle and genetic disorders. Therefore HTLV-1 triggers a phenotype-specific miR signature consistent with the preleukemic HTLV-1+CD4+ phenotype.

Authors’ Affiliations

(1)
Oncovirologie et de Biotherapies, UMR5239 CNRS/ENS Lyon/UCBL/HCL, Hopital Pierre Benite, Lyon, France
(2)
Oncovirologie et de Biotherapies, Centre Léon Berard, Lyon, France
(3)
ProfileXpert, Neurobiotec Service, Bron, 69500, France

Copyright

Advertisement